https://pubmed.ncbi.nlm.nih.gov/21885251/
Abstract
Malignant brain cancer persists as a major disease of morbidity
and mortality. The failure to recognize brain cancer as a disease of
energy metabolism has contributed in large part to the failure in
management. As long as brain tumor cells have access to glucose and
glutamine, the disease will progress. The current standard of care
provides brain tumors with access to glucose and glutamine. The high fat
low carbohydrate ketogenic diet (KD) will target glucose availability
and possibly that of glutamine when administered in carefully restricted
amounts to reduce total caloric intake and circulating levels of
glucose. The restricted KD (RKD) targets major signaling pathways
associated with glucose and glutamine metabolism including the
IGF-1/PI3K/Akt/Hif pathway. The RKD is anti-angiogenic, anti-invasive,
anti-inflammatory, and pro-apoptotic when evaluated in mice with
malignant brain cancer. The therapeutic efficacy of the restricted KD
can be enhanced when combined with drugs that also target glucose and
glutamine. Therapeutic efficacy of the RKD was also seen against
malignant gliomas in human case reports. Hence, the RKD can be an
effective non-toxic therapeutic option to the current standard of care
for inhibiting the growth and invasive properties of malignant brain
cancer.
Seyfried TN, Marsh
J, Shelton LM, Huysentruyt LC, Mukherjee P. Is the restricted ketogenic
diet a viable alternative to the standard of care for managing malignant
brain cancer? Epilepsy Res. 2012 Jul;100(3):310-26. doi:
10.1016/j.eplepsyres.2011.06.017. Epub 2011 Aug 31. PMID: 21885251.
